---
title: "Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296915210.md"
description: "Johnson & Johnson received FDA approval for IMAAVY (nipocalimab-aahu), the first targeted therapy for warm autoimmune hemolytic anemia in adults and pediatric patients aged 12 and older. Approved following a Priority Review, IMAAVY targets pathogenic IgG autoantibodies, offering a safer alternative to traditional corticosteroids. Clinical trials showed significant improvements in hemoglobin levels and reduced fatigue. JNJ shares were down 0.33% in premarket trading."
datetime: "2026-08-25T12:22:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296915210.md)
  - [en](https://longbridge.com/en/news/296915210.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296915210.md)
generator: "portal-rs"
---

# Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment

On Tuesday, the U.S. Food and Drug Administration (FDA) approved **Johnson & Johnson’s** (NYSE:JNJ) IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA).

## New Therapy for Rare Autoantibody Disease

The agency cleared the medication for adults and pediatric patients aged 12 and older who currently receive or previously received corticosteroids.

Following a Priority Review, IMAAVY stands as the very first therapy specifically proven safe and effective for this rare, life-threatening condition.

In patients suffering from wAIHA, pathogenic immunoglobulin G (IgG) autoantibodies attach to and destroy healthy red blood cells. This destructive process causes severe anemia, profound fatigue, and an elevated risk of morbidity and mortality.

Before this approval, standard treatments only included corticosteroids and generalized immunosuppressants.

 **Read Also: Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade** 

Those traditional therapies suppress the entire immune system instead of precisely targeting the IgG autoantibodies driving the illness.

## Clinical Trial Efficacy And Established Safety

The Phase 2/3 ENERGY study evaluated the drug’s effectiveness, using durable hemoglobin (Hgb) response as the primary endpoint to measure meaningful increases over time.

The randomized, placebo-controlled trial revealed that approximately three times as many patients receiving the approved dose of IMAAVY achieved durable Hgb levels by 24 weeks compared to the placebo group.

Overall, patients taking the medication demonstrated a mean Hgb increase of 1g/dL at Week 1. Additionally, the drug helped reduce exhaustion, showing a 3.5-point higher mean FACIT-Fatigue score versus placebo at Week 24.

The FDA previously approved IMAAVY in April 2025 for generalized myasthenia gravis patients 12 years and older who are acetylcholine receptor or muscle-specific kinase antibody positive.

**JNJ Price Action:** Johnson & Johnson shares were down 0.33% at $270.81 during premarket trading on Tuesday. The stock is approaching its 52-week high of $276.47, according to Benzinga Pro data.

 **Read Also: Coinbase CEO Tells Entrepreneurs ‘Go Try the Idea,’ ‘Fall Flat on Your Face’ Rather Than Fear Failure** 

*Image via Shutterstock*

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [COIN.US](https://longbridge.com/en/quote/COIN.US.md)

## Related News & Research

- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Arqit, Es’hailSat and AIEE Demonstrate Quantum-Safe Satellite Security | ARQQ Stock News](https://longbridge.com/en/news/297664164.md)
- [Axia Energia announces shareholder meeting](https://longbridge.com/en/news/298072268.md)
- [Litel Participações to pay BRL 61 million in interest on equity starting Sept. 2](https://longbridge.com/en/news/297690312.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**